HDAC, BTK: Method of Using HDAC Inhibitors, Alone or in Combination with BTK Inhibitors, for Treating Chronic Lymphocytic Leukemia (CLL)

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CALL OUR OFFICE

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

16MA023N